Selected research
Industry Research
Monoclonal Antibody VEGF Inhibitors Industry Research Report 2026
Market perspective
The global Monoclonal Antibody VEGF Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Monoclonal Antibody VEGF Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Monoclonal Antibody VEGF Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Monoclonal Antibody VEGF Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Monoclonal Antibody VEGF Inhibitors include Amgen, Amneal Pharmaceuticals,, Celltrion Healthcare, Coherus BioSciences, Eli Lilly, Novartis, Pfizer, Roche and Boan Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Monoclonal Antibody VEGF Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Monoclonal Antibody VEGF Inhibitors Market by Company
Amgen
Amneal Pharmaceuticals,
Celltrion Healthcare
Coherus BioSciences
Eli Lilly
Novartis
Pfizer
Roche
Boan Biotech
Jiangsu Hengrui Pharmaceuticals
Qilu Pharma
SinoCellTech
Innovent
Chia Tai Tianqing
Monoclonal Antibody VEGF Inhibitors Segment by Type
Bevacizumab
Brolucizumab
Faricimab
Ramucirumab
Ranibizumab
Other
Monoclonal Antibody VEGF Inhibitors Segment by Application
Degenerative Eye Diseases
Cancer
Other
Monoclonal Antibody VEGF Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody VEGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody VEGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody VEGF Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Monoclonal Antibody VEGF Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Monoclonal Antibody VEGF Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Monoclonal Antibody VEGF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Monoclonal Antibody VEGF Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Monoclonal Antibody VEGF Inhibitors Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Monoclonal Antibody VEGF Inhibitors Revenue of Manufacturers (2021-2026)
Table 9. Global Monoclonal Antibody VEGF Inhibitors Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Monoclonal Antibody VEGF Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Monoclonal Antibody VEGF Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Monoclonal Antibody VEGF Inhibitors, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Monoclonal Antibody VEGF Inhibitors, Product Type & Application
Table 14. Global Monoclonal Antibody VEGF Inhibitors Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Monoclonal Antibody VEGF Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Amgen Company Information
Table 19. Amgen Business Overview
Table 20. Amgen Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Amgen Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 22. Amgen Recent Developments
Table 23. Amneal Pharmaceuticals, Company Information
Table 24. Amneal Pharmaceuticals, Business Overview
Table 25. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 27. Amneal Pharmaceuticals, Recent Developments
Table 28. Celltrion Healthcare Company Information
Table 29. Celltrion Healthcare Business Overview
Table 30. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 32. Celltrion Healthcare Recent Developments
Table 33. Coherus BioSciences Company Information
Table 34. Coherus BioSciences Business Overview
Table 35. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 37. Coherus BioSciences Recent Developments
Table 38. Eli Lilly Company Information
Table 39. Eli Lilly Business Overview
Table 40. Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 42. Eli Lilly Recent Developments
Table 43. Novartis Company Information
Table 44. Novartis Business Overview
Table 45. Novartis Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Novartis Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 47. Novartis Recent Developments
Table 48. Pfizer Company Information
Table 49. Pfizer Business Overview
Table 50. Pfizer Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Pfizer Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 52. Pfizer Recent Developments
Table 53. Roche Company Information
Table 54. Roche Business Overview
Table 55. Roche Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Roche Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 57. Roche Recent Developments
Table 58. Boan Biotech Company Information
Table 59. Boan Biotech Business Overview
Table 60. Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 62. Boan Biotech Recent Developments
Table 63. Jiangsu Hengrui Pharmaceuticals Company Information
Table 64. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 65. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 67. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 68. Qilu Pharma Company Information
Table 69. Qilu Pharma Business Overview
Table 70. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 72. Qilu Pharma Recent Developments
Table 73. SinoCellTech Company Information
Table 74. SinoCellTech Business Overview
Table 75. SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 77. SinoCellTech Recent Developments
Table 78. Innovent Company Information
Table 79. Innovent Business Overview
Table 80. Innovent Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Innovent Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 82. Innovent Recent Developments
Table 83. Chia Tai Tianqing Company Information
Table 84. Chia Tai Tianqing Business Overview
Table 85. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Portfolio
Table 87. Chia Tai Tianqing Recent Developments
Table 88. Global Monoclonal Antibody VEGF Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 89. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2021-2026) & (K Units)
Table 90. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2021-2026)
Table 91. Global Monoclonal Antibody VEGF Inhibitors Sales by Region (2027-2032) & (K Units)
Table 92. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Region (2027-2032)
Table 93. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2021-2026) & (US$ Million)
Table 94. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2021-2026)
Table 95. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region (2027-2032) & (US$ Million)
Table 96. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Region (2027-2032)
Table 97. North America Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 98. North America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units)
Table 99. North America Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units)
Table 100. North America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 101. North America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 102. Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 103. Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units)
Table 104. Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units)
Table 105. Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 106. Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 107. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 108. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units)
Table 109. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units)
Table 110. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 111. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 112. South America Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. South America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units)
Table 114. South America Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units)
Table 115. South America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 116. South America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 117. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 118. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2026) & (K Units)
Table 119. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (2027-2032) & (K Units)
Table 120. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 121. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 122. Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021-2026) & (K Units)
Table 123. Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2027-2032) & (K Units)
Table 124. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021-2026)
Table 125. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2027-2032)
Table 126. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021-2026) & (US$ Million)
Table 127. Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2027-2032) & (US$ Million)
Table 128. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021-2026)
Table 129. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2027-2032)
Table 130. Global Monoclonal Antibody VEGF Inhibitors Price by Type (2021-2026) & (US$/Unit)
Table 131. Global Monoclonal Antibody VEGF Inhibitors Price by Type (2027-2032) & (US$/Unit)
Table 132. Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021-2026) & (K Units)
Table 133. Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2027-2032) & (K Units)
Table 134. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021-2026)
Table 135. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2027-2032)
Table 136. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021-2026) & (US$ Million)
Table 137. Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2027-2032) & (US$ Million)
Table 138. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021-2026)
Table 139. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2027-2032)
Table 140. Global Monoclonal Antibody VEGF Inhibitors Price by Application (2021-2026) & (US$/Unit)
Table 141. Global Monoclonal Antibody VEGF Inhibitors Price by Application (2027-2032) & (US$/Unit)
Table 142. Key Raw Materials
Table 143. Raw Materials Key Suppliers
Table 144. Monoclonal Antibody VEGF Inhibitors Distributors List
Table 145. Monoclonal Antibody VEGF Inhibitors Customers List
Table 146. Monoclonal Antibody VEGF Inhibitors Industry Trends
Table 147. Monoclonal Antibody VEGF Inhibitors Industry Drivers
Table 148. Monoclonal Antibody VEGF Inhibitors Industry Restraints
Table 149. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Monoclonal Antibody VEGF Inhibitors Product Image
Figure 5. Global Monoclonal Antibody VEGF Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Monoclonal Antibody VEGF Inhibitors Market Size (2021-2032) & (US$ Million)
Figure 7. Global Monoclonal Antibody VEGF Inhibitors Sales (2021-2032) & (K Units)
Figure 8. Global Monoclonal Antibody VEGF Inhibitors Average Price (US$/Unit) & (2021-2032)
Figure 9. Bevacizumab Product Image
Figure 10. Brolucizumab Product Image
Figure 11. Faricimab Product Image
Figure 12. Ramucirumab Product Image
Figure 13. Ranibizumab Product Image
Figure 14. Other Product Image
Figure 15. Degenerative Eye Diseases Product Image
Figure 16. Cancer Product Image
Figure 17. Other Product Image
Figure 18. Global Monoclonal Antibody VEGF Inhibitors Revenue Share by Manufacturers in 2025
Figure 19. Global Manufacturers of Monoclonal Antibody VEGF Inhibitors, Manufacturing Sites & Headquarters
Figure 20. Global Top 5 and 10 Monoclonal Antibody VEGF Inhibitors Players Market Share by Revenue in 2025
Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 22. Global Monoclonal Antibody VEGF Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 23. Global Monoclonal Antibody VEGF Inhibitors Sales by Region in 2025
Figure 24. Global Monoclonal Antibody VEGF Inhibitors Revenue by Region in 2025
Figure 25. North America Monoclonal Antibody VEGF Inhibitors Market Size by Country in 2025
Figure 26. North America Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032)
Figure 27. North America Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021-2032)
Figure 28. United States Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Canada Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. Mexico Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. Europe Monoclonal Antibody VEGF Inhibitors Market Size by Country in 2025
Figure 32. Europe Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032)
Figure 33. Europe Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021-2032)
Figure 34. Germany Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. France Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. U.K. Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Italy Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Russia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Spain Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Netherlands Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Switzerland Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Sweden Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Poland Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Asia Pacific Monoclonal Antibody VEGF Inhibitors Market Size by Country in 2025
Figure 45. Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032)
Figure 46. Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021-2032)
Figure 47. China Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. Japan Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. South Korea Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. India Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Australia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Taiwan Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Southeast Asia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Southeast Asia Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. South America Monoclonal Antibody VEGF Inhibitors Market Size by Country in 2025
Figure 56. South America Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032)
Figure 57. South America Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021-2032)
Figure 58. Brazil Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. Argentina Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Chile Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 61. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Market Size by Country in 2025
Figure 62. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales Market Share by Country (2021-2032)
Figure 63. Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Country (2021-2032)
Figure 64. Egypt Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 65. South Africa Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. Israel Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 67. Türkiye Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 68. GCC Countries Monoclonal Antibody VEGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 69. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021-2032)
Figure 70. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021-2032)
Figure 71. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Type (2021-2032)
Figure 72. Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021-2032)
Figure 73. Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021-2032)
Figure 74. Global Monoclonal Antibody VEGF Inhibitors Price (US$/Unit) by Application (2021-2032)
Figure 75. Monoclonal Antibody VEGF Inhibitors Value Chain
Figure 76. Monoclonal Antibody VEGF Inhibitors Production Mode & Process
Figure 77. Direct Comparison with Distribution Share
Figure 78. Distributors Profiles
Figure 79. Monoclonal Antibody VEGF Inhibitors Industry Opportunities and Challenges
Scope & coverage.
Types
- Bevacizumab
- Brolucizumab
- Faricimab
- Ramucirumab
- Ranibizumab
- Other
Applications
- Degenerative Eye Diseases
- Cancer
- Other
Companies covered
- Amgen
- Amneal Pharmaceuticals,
- Celltrion Healthcare
- Coherus BioSciences
- Eli Lilly
- Novartis
- Pfizer
- Roche
- Boan Biotech
- Jiangsu Hengrui Pharmaceuticals
- Qilu Pharma
- SinoCellTech
- Innovent
- Chia Tai Tianqing
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Monoclonal Antibody VEGF Inhibitors Market Size (2021-2032)
- 2.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales (2021-2032)
- 2.2.3 Global Monoclonal Antibody VEGF Inhibitors Market Average Price (2021-2032)
- 2.3 Monoclonal Antibody VEGF Inhibitors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Bevacizumab
- 2.3.3 Brolucizumab
- 2.3.4 Faricimab
- 2.3.5 Ramucirumab
- 2.3.6 Ranibizumab
- 2.3.7 Other
- 2.4 Monoclonal Antibody VEGF Inhibitors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Degenerative Eye Diseases
- 2.4.3 Cancer
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Monoclonal Antibody VEGF Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Monoclonal Antibody VEGF Inhibitors Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Monoclonal Antibody VEGF Inhibitors Revenue of Manufacturers (2021-2026)
- 3.4 Global Monoclonal Antibody VEGF Inhibitors Average Price by Manufacturers (2021-2026)
- 3.5 Global Monoclonal Antibody VEGF Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Monoclonal Antibody VEGF Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Monoclonal Antibody VEGF Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of Monoclonal Antibody VEGF Inhibitors, Established Date
- 3.9 Global Monoclonal Antibody VEGF Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Amgen
- 4.1.1 Amgen Company Information
- 4.1.2 Amgen Business Overview
- 4.1.3 Amgen Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Amgen Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.1.5 Amgen Recent Developments
- 4.2 Amneal Pharmaceuticals,
- 4.2.1 Amneal Pharmaceuticals, Company Information
- 4.2.2 Amneal Pharmaceuticals, Business Overview
- 4.2.3 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amneal Pharmaceuticals, Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.2.5 Amneal Pharmaceuticals, Recent Developments
- 4.3 Celltrion Healthcare
- 4.3.1 Celltrion Healthcare Company Information
- 4.3.2 Celltrion Healthcare Business Overview
- 4.3.3 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Celltrion Healthcare Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.3.5 Celltrion Healthcare Recent Developments
- 4.4 Coherus BioSciences
- 4.4.1 Coherus BioSciences Company Information
- 4.4.2 Coherus BioSciences Business Overview
- 4.4.3 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Coherus BioSciences Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.4.5 Coherus BioSciences Recent Developments
- 4.5 Eli Lilly
- 4.5.1 Eli Lilly Company Information
- 4.5.2 Eli Lilly Business Overview
- 4.5.3 Eli Lilly Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Eli Lilly Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.5.5 Eli Lilly Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Roche
- 4.8.1 Roche Company Information
- 4.8.2 Roche Business Overview
- 4.8.3 Roche Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Roche Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.8.5 Roche Recent Developments
- 4.9 Boan Biotech
- 4.9.1 Boan Biotech Company Information
- 4.9.2 Boan Biotech Business Overview
- 4.9.3 Boan Biotech Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Boan Biotech Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.9.5 Boan Biotech Recent Developments
- 4.10 Jiangsu Hengrui Pharmaceuticals
- 4.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.10.3 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Jiangsu Hengrui Pharmaceuticals Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.11 Qilu Pharma
- 4.11.1 Qilu Pharma Company Information
- 4.11.2 Qilu Pharma Business Overview
- 4.11.3 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Qilu Pharma Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.11.5 Qilu Pharma Recent Developments
- 4.12 SinoCellTech
- 4.12.1 SinoCellTech Company Information
- 4.12.2 SinoCellTech Business Overview
- 4.12.3 SinoCellTech Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 SinoCellTech Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.12.5 SinoCellTech Recent Developments
- 4.13 Innovent
- 4.13.1 Innovent Company Information
- 4.13.2 Innovent Business Overview
- 4.13.3 Innovent Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Innovent Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.13.5 Innovent Recent Developments
- 4.14 Chia Tai Tianqing
- 4.14.1 Chia Tai Tianqing Company Information
- 4.14.2 Chia Tai Tianqing Business Overview
- 4.14.3 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Chia Tai Tianqing Monoclonal Antibody VEGF Inhibitors Product Portfolio
- 4.14.5 Chia Tai Tianqing Recent Developments
5 Global Monoclonal Antibody VEGF Inhibitors Market Scenario by Region
- 5.1 Global Monoclonal Antibody VEGF Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021-2032
- 5.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2021-2026
- 5.2.2 Global Monoclonal Antibody VEGF Inhibitors Sales by Region: 2027-2032
- 5.3 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2021-2032
- 5.3.1 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2021-2026
- 5.3.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Region: 2027-2032
- 5.4 North America Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
- 5.4.1 North America Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
- 5.4.3 North America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
- 5.5.1 Europe Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
- 5.5.3 Europe Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
- 5.6.1 Asia Pacific Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
- 5.7.1 South America Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
- 5.7.3 South America Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Monoclonal Antibody VEGF Inhibitors Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021-2032)
- 6.1.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Type (2021-2032)
- 6.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Type (2021-2032)
- 6.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Type (2021-2032)
- 6.3 Global Monoclonal Antibody VEGF Inhibitors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021-2032)
- 7.1.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Monoclonal Antibody VEGF Inhibitors Sales Market Share by Application (2021-2032)
- 7.2 Global Monoclonal Antibody VEGF Inhibitors Revenue by Application (2021-2032)
- 7.2.1 Global Monoclonal Antibody VEGF Inhibitors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Monoclonal Antibody VEGF Inhibitors Revenue Market Share by Application (2021-2032)
- 7.3 Global Monoclonal Antibody VEGF Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Monoclonal Antibody VEGF Inhibitors Value Chain Analysis
- 8.1.1 Monoclonal Antibody VEGF Inhibitors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Monoclonal Antibody VEGF Inhibitors Production Mode & Process
- 8.2 Monoclonal Antibody VEGF Inhibitors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Monoclonal Antibody VEGF Inhibitors Distributors
- 8.2.3 Monoclonal Antibody VEGF Inhibitors Customers
9 Global Monoclonal Antibody VEGF Inhibitors Analyzing Market Dynamics
- 9.1 Monoclonal Antibody VEGF Inhibitors Industry Trends
- 9.2 Monoclonal Antibody VEGF Inhibitors Industry Drivers
- 9.3 Monoclonal Antibody VEGF Inhibitors Industry Opportunities and Challenges
- 9.4 Monoclonal Antibody VEGF Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst